Victoria English from MedNous (Evernow Publishing Ltd) spoke with Paola Pozzi, Partner at Sofinnova Partners, about the Sofinnova Cell and Gene Therapy report. The report explores key industry trends shaping the future of advanced therapies, including: • The expanding role of cell & gene therapies in venture capital and M&A • The increasing importance of delivery technologies in advancing treatments • A shift in investment focus toward clinical-stage biotech Read MedNous’ latest piece to learn more and stay tuned for the Sofinnova Cell and Gene Therapy report coming soon.
The February edition of MedNous is now out, featuring a review of new concepts for the development of Alzheimer's disease drugs. We also report on FDA approval of a non-opioid drug for pain. Next to this is a research article by the CEO of PharmNovo of Sweden describing an experimental opioid treatment for the same indication. Trends in investment for cell and gene therapies are detailed in a report by Sofinnova. Finally, do you want to understand more about the federated analysis of data? Then read Philip Quinlan's article about a new project between academia and industry in the UK. For a complimentary copy of this issue, please email editor@evernow.eu.